Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Misha V. Blagosklonny subsequently
Relocated to the United States, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diversified biomedical themes, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
Trial article.
 
After authoring seven papers during a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Mikhail Blagosklonny published anumber of experimental research articles and theoretical articles as lead
Writer. The abovementioned sole-author papers
Encompassed two crucial themes.
The first of these explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Exploiting their resistance. The results and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the publication was
Named, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author articles
Is a research methodology to develop knowledge via
Uniting several facts together from seemingly unrelated areas.
This results in new concepts containing testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant result discovered by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others don' t even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Preventing body aging — in other words, “preventing cancer
Via remainng young. ” His laboratory closely worked together with
Andrei Gudkov’s and finalized research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of additional anti-aging
Medications besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging drugs to be taken by humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://ouroboros.wordpress.com/2007/03/06/an-anti-aging-drug-today-rapamycin/
https://www.tandfonline.com/doi/pdf/10.4161/cbt.8.9.8899
https://tandfonline.com/doi/abs/10.4161/cbt.8.9.8899